Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Measuring the Outcomes of International Oncology Regulatory Collaboration in Canada from 2019 to 2025: Project Orbis. Local targets link to admitted publications; unresolved targets remain external evidence.
Project Orbis: global collaborative review program
10.1158/1078-0432.ccr-20-3292 · 2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Index of application status transparency and availability of public information for Project Orbis agencies
10.22270/ijdra.v12i3.699 · 2024 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
2025 · External reference
Strengthening the use of international collaborative regulatory assessments and regulatory alignment – implications for global convergence
10.1007/s43441-025-00817-8 · 2025 · External reference
Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis
10.1016/s1470-2045(24)00158-x · 2024 · External reference
From the European medicines agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit
10.1016/s1470-2045(22)00701-x · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Time to market for drugs approved in Canada between 2014 and 2018: an observational study
10.1136/bmjopen-2020-047557 · 2021 · External reference
Is Canada moving towards a more agile regulatory approval and reimbursement process with a shifting role for real‐world evidence (RWE) for oncology drugs?
10.3390/curroncol31090414 · 2024 · External reference
Clinical benefit, reimbursement outcomes, and prices of FDA‐approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis
10.1016/s1470-2045(24)00286-9 · 2024 · External reference
Therapeutic value of oncology drugs approved by Health Canada through Project Orbis: a cross‐sectional study
10.1016/j.jcpo.2025.100635 · 2025 · External reference
Project Orbis: the UK experience after 1 year
10.1016/s1470-2045(22)00377-1 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
